linjc16/ctgov huggingface dataset:
Robotic Upper-Limb Neurorehabilitation in Chronic Stroke Patient

Study Overview
=================
Brief Summary
-----------------
We have established the feasibility and effectiveness of robot-aided rehabilitation in stroke patients using a robot for neurological rehabilitation designed and built by MIT. Results of a pilot study of 20 patients were promising and showed that robot therapy is safe, tolerated by patients and produces a significant, measurable benefit. We propose to test that the robotic upper extremity trainer is an acceptable cost effective adjunct to standard occupational therapy for patients with dysfunction of the shoulder and elbow due to hemiparetic stroke in a VA rehabilitation program.

Official Title
-----------------
Evaluation of Robotic Upper Extremity Neuro-Rehabilitation

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Device: Upper extremity robot
* Other: Traditional Supervised Upper Extremity Exercises


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic Stroke Manual Muscle Score of Grade 3 or lower in at least one muscle of the affected arm Exclusion Criteria: Acute Stroke Contracture or orthopedic problems limiting the movement of the affected arm Visual deficit such that the participant cannot see the test pattern on the robot trainer Serious complicating medical illness Botox treatment to the involved arm within three months of enrollment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Robot exercise group | Device: Upper extremity robot<br>* Robotic upper extremity neuro-rehabilitation<br>|
| Active Comparator: 2<br>Traditional exercise group | Device: Upper extremity robot<br>* Robotic upper extremity neuro-rehabilitation<br>Other: Traditional Supervised Upper Extremity Exercises<br>* Arm ergometer, reaching, and stretching exercises<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Upper limb Motor Status Score, Wolf Motor Function Test, Motor Power Assessment, and Fugl-Meyer Upper Extremity Motor Performance Test |  | The Primary Outcome measures were performed at baseline, after completion of 18 sessions of intervention and at 3 months follow-up. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Robot, Stroke, Upper Extremity
Ghrelin Levels in Patients With Protein C Deficiency

Study Overview
=================
Brief Summary
-----------------
In rodents with protein C deficiency elevated levels of ghrelin has been observed. The purpose of this study is to investigate if patients with protein C deficiency also have elevated levels of ghrelin, and if so, how this affects the patients. 30 patients with protein C deficiency and 30 healthy BMI and gender matched controls are recruited. Bloodsamples are taken in order to measure ghrelin and GH levels and other metabolic parameters. The patients and controls are also asked to answer a questionaire regarding appetite. If patients with protein C deficiency have higher levels of ghrelin than the general population, this will lead to new studies that will perhaps help us understand the importance of ghrelin in humans.

Official Title
-----------------
Investigation of Ghrelin Levels in Patients With Protein C Deficiency

Conditions
-----------------
Protein C Deficiency

Intervention / Treatment
-----------------
* Genetic: Protein C deficiency


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: protein C deficiency or healthy subjects age 18-70 BMI 18-35 written statement to join the study Exclusion Criteria: chronic illness, apart from protein C deficiency and lifestyle diseases everyday medication apart from statins, oral diabetes medication and antihypertensive drugs. blood donation within three months prior to the investigation. Alcohol abuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with protein C deficiency<br>Patient and control group are compared regarding ghrelin, growth hormone levels and appetite, and no other intervention is made. | Genetic: Protein C deficiency<br>* The effect of protein C deficiency on ghrelin levels are investigated.<br>|
| Healthy controls<br>Patient and control group are compared regarding ghrelin, growth hormone levels and appetite, and no other intervention is made. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| acyl ghrelin and des acyl ghrelin measured in mg/dl |  | 6 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Growth hormone measured in pmol/L |  | 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ghrelin, growth hormone, protein C deficiency, appetite
The Effects of Large Head MoM Hip Prosthesis on Soft Tissue: Study With 3 Tesla NMR

Study Overview
=================
Brief Summary
-----------------
Symptomatic and asymptomatic patients wearing Metal on Metal hip prosthesis will be enrolled in the study and periimplant pseudotumors will be searched by means of NMR (Nuclear Magnetic Resonance).

Official Title
-----------------
The Effects of Large Head Metal on Metal (MOM) Hip Prosthesis on Soft Tissue: Study With 3 Tesla Nuclear Magnetic Resonance (NMR)

Conditions
-----------------
Prostheses and Implants

Intervention / Treatment
-----------------
* Procedure: NMR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients wearing MoM hip prosthesis Head >= 36 mm Exclusion Criteria: Presence of ferromagnetic implants and/or presence of clinical situations that are not compatible with NMR
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Symptomatic<br>Patients with pain and or other sign of prothesis failure | Procedure: NMR<br>* NMR<br>|
| Asymptomatic<br>Patients with regular clinical and radiographic evolution of the implant. No pain | Procedure: NMR<br>* NMR<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of pseudotumor | First NMR will be offered to patients in a period comprised between 3 and 6 yrs from surgery | at first NMR, between 3 and 6 yrs from surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hip Prosthesis
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

Study Overview
=================
Brief Summary
-----------------
The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD). The primary objective is to show efficacy of the two experimental treatment strategies. Secondary objectives are to further evaluate efficacy, show safety and feasibility and perform correlative studies.

Official Title
-----------------
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

Conditions
-----------------
Classical Hodgkin Lymphoma

Intervention / Treatment
-----------------
* Drug: Nivolumab
* Drug: Adriamycin
* Drug: Vinblastine
* Drug: Dacarbazine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically proven classical HL First diagnosis, no previous treatment Age: 18-60 years Stage I, IIA with risk factors a-d, IIB with RF c-d: large mediastinal mass extranodal lesions elevated ESR ≥ 3 nodal areas confirmed by central review. Exclusion Criteria: Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL) History of other malignancy ≤ 5 years Prior chemotherapy or radiation therapy Concurrent disease precluding protocol treatment Pregnancy, lactation Non-compliance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm A<br>4 Cycles of Nivolumab plus AVD followed by IF-RT (30 Gy) | Drug: Nivolumab<br>* Infusion of Nivolumab<br>Drug: Adriamycin<br>* Infusion of Adriamycin<br>Drug: Vinblastine<br>* Infusion of Vinblastine<br>Drug: Dacarbazine<br>* Infusion of Dacarbazine<br>|
| Experimental: Arm B<br>4 Cycles of Nivolumab, followed by 2 cycles of Nivolumab plus AVD, followed by 2 Cycles of AVD followed by IF-RT (30 Gy) | Drug: Nivolumab<br>* Infusion of Nivolumab<br>Drug: Adriamycin<br>* Infusion of Adriamycin<br>Drug: Vinblastine<br>* Infusion of Vinblastine<br>Drug: Dacarbazine<br>* Infusion of Dacarbazine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete Remission Rate |  | 4 to 6 weeks after end of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment related Morbidity |  | 1 year after end of treatment | 
| Progression Free Survival |  | 1 and 3 years after end of treatment | 
| Overall Survival |  | 1 and 3 years after end of treatment |
Lead Detoxifying Effects of Ascorbic Acid Among School Going Adolescents of Karachi- A Cluster Randomized Control Trial

Study Overview
=================
Brief Summary
-----------------
The toxic nature of lead has been recognized ubiquitous for than 2,000 years and today it is a persistent and common environmental contaminant in most parts of the world. Vitamin C is a strong antioxidant and a metabolic co factor playing an important role in many biological processes and biochemical functions (hydroxylation reactions). The research objective is to assess the effect of oral ascorbic acid supplementation 500mg and 250 mg once a day for 4 weeks on Blood Lead level among school going urban adolescents, using a cluster randomized trial study design. Ascorbic Acid (vitamin C) 250 and 500 mg will be administered in two study arms.

Official Title
-----------------
Lead Detoxifying Effects of Ascorbic Acid Among School Going Adolescents of Karachi- A Cluster Randomized Control Trial

Conditions
-----------------
Elevated Blood Lead Levels

Intervention / Treatment
-----------------
* Drug: Ascorbic Acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1-school going adolescents, aged 13-18 years. Exclusion Criteria: Children with history or presence of chronic illness or bleeding disorders, requiring red blood cell transfusion, dialysis Using multivitamins Those who planning to leave study place within 2 months of start of study

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm A<br>Ascorbic Acid 250 mg in tablet form was used. | Drug: Ascorbic Acid<br>* Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.<br>* Other names: Vitamin C;|
| Experimental: Arm B<br>Ascorbic Acid 500 mg in tablet form was used. | Drug: Ascorbic Acid<br>* Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.<br>* Other names: Vitamin C;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood Lead Level | Mean Change in blood lead level is the main outcome of the study. It will be recorded as continuous variable and unit of measurement will be μg/dl. Blood lead levels will be assessed at baseline before the start of intervention and at the end of the 4 weeks of intervention period in both arms. Mean change will be calculated by taking difference between two the points as follow up (4 weeks) Blood lead levels minus baseline Blood Lead level. | 4 weeks |
Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed Combination

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the ocular hypotensive effect of Bimatoprost and the potential additional effect of the Bimatoprost/Timolol fixed combination in eyes with ocular hypertension, primary open angle glaucoma or exfoliation glaucoma.

Official Title
-----------------
Efficacy Of The Bimatoprost/Timolol Fixed Combination In Patients Treated With Bimatoprost for Primary Open Angle Glaucoma, Exfoliation Glaucoma or Ocular Hypertension.

Conditions
-----------------
Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Bimatoprost and Bimatoprost/Timolol fixed combination.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary open angle glaucoma Exfoliation glaucoma Ocular hypertension Exclusion Criteria: Younger than 18 years old Inability to understand and/or follow study requirements Women of childbearing potential not using reliable birth control, pregnant or lactating women History of chronic obstructive pulmonary disease, heart failure, 2nd or 3rd AV block Anticipated modification of treatment for systemic hypertension during the study period History of ocular herpes, corneal scarring, conventional or laser surgery or macular pathology History of allergy, poor tolerability or poor response to study medication Best corrected visual acuity less than 0.4 Significant visual field defect (MD<15.0 dB)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Bimatoprost and Bimatoprost/Timolol fixed combination.|Following an appropriate wash-out period, participants were given a 5-week long treatment with Bimatoprost 0.03% once daily in the evening followed by a further 5-week long treatment with the Bimatoprost 0.03%/Timolol 0.5% fixed combination administered in the evening.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean diurnal intraocular pressure |  | Five weeks on each medication | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma, Ocular Hypertension, Lumigan, Ganfort
5 Year Radiological and Clinical Results From Patients Operated for Hallux Valgus Deformity.

Study Overview
=================
Brief Summary
-----------------
Retrospective study of patients operated for hallux valgus deformity at our hospital (ostfold hospital trust) 5 years ago. Patients will be clinically examined, a weighted radiograph of the foot (traditional and newer parameters will be evaluated) and patient reported outcome measures (PROM) scores will be collected.

Official Title
-----------------
Radiological Outcome vs.Patient Reported Clinical Outcome 5 Years Post Hallux Valgus Surgery

Conditions
-----------------
Hallux Valgus

Intervention / Treatment
-----------------
* Procedure: 5 year follow up on patients operated for hallux valgus deformity


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients (18-80 years at time of surgery) operated for hallux valgus deformity at ostfold hospital trust 2016-2018 Exclusion Criteria: Not able to speak/write/read norwegian language

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: 5 year follow up on patients operated for hallux valgus deformity|Clinical and radiological control of patients operated for hallux valgus deformity between 2016-2018.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical 5 year outcome | Clinical (Manchester-oxford Foot Questionnaire (MOxFQ) | Data collection during 2023, completion during 2024 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical VAS 5 year outcome | Visual analogue scale (VAS 0-10) | Data collection during 2023, completion during 2024 | 
| Clinical Likert scale 5 year outcome | Likert scale | Data collection during 2023, completion during 2024 | 
| Radiological outcomes | Measurement of correction | Until 2024 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Radiological outcome, Clinical outcome
Evaluation of Diabetic Foot Wound Healing Using Hydrogel/Nano Silver-based Dressing vs. Traditional Dressing

Study Overview
=================
Brief Summary
-----------------
Background: The wound dressings perform a crucial role in the cutaneous wounds' management due to their ability to protect wounds and promote dermal and epidermal tissue regeneration. Objective: the aim of the present study to evaluate the effectiveness of using hydrogel/nano silver-based dressing vs. traditional dressing on diabetic foot wound healing. Approach: Sixty patients with type-2 diabetes hospitalized for diabetic foot wound treatment were recruited from selected Surgical departments at Kasr Al-Aini university hospital.

Detailed Description
-----------------
Data Collection: The patients of group-I wounds were cleaned using normal saline; then, the wounds were closed firmly with hyderogel\nano silver dressing. The dressing was changed every two days according to dressing manufacture instruction. When the dressing was opened after three days, the wound was assessed for granulation tissue, wound, and discharge size. The patients of group II wounds were dresses using a traditional method, cleaned by normal saline, use of betadine antiseptic; then they were secured with clean linen gauze. The dressing was changed once daily. The wound healing process of the two groups was then assessed for three consecutive weeks.

Official Title
-----------------
Evaluation of Diabetic Foot Wound Healing Using Hydrogel/Nano Silver-based Dressing vs. Traditional Dressing: A Prospective Randomized Control Study

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Procedure: Hydrogel/nano silver-based dressing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetes Type I and Type II patient with diabetic foot ulcer age ranged 35-55 years old Willing to participate Exclusion Criteria: unwilling to participate.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: hydrogel/nano silver-based dressing<br>hydrogel/nano silver-based dressing | Procedure: Hydrogel/nano silver-based dressing<br>* compare the effectiveness of using hydrogel/nano silver-based dressing vs. traditional dressing on diabetic foot wound healing.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the percentage of a reduction rate of the diabetic foot ulcer after intervention | assess of diabetic foot ulcers size sq mm | 3 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetic foot ulcer
Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy and safety of pimecrolimus cream 1% in its registered indication (treatment of patients > 3 months of age with mild to moderate atopic dermatitis) This study is not enrolling patients in the United States.

Conditions
-----------------
Atopic Dermatitis

Intervention / Treatment
-----------------
* Drug: Pimecrolimus Cream 1%


Participation Criteria
=================
Eligibility Criteria
-----------------
The patient population must consist of male or female outpatients, age ≥3 months old with mild to moderate atopic dermatitis (IGA ≥ 1). Exclusion criteria are pregnancy, having active viral infections at the site(s) of treatment, presenting with systemic malignancy or active lymphoproliferative diseases/disorders, receiving phototherapy or immunosuppressive therapy, having used tacrolimus ointment and known allergy or hypersensitivity.

Ages Eligible for Study
-----------------
Minimum Age: 3 Months

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pimecrolimus Cream 1%|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Investigator Global Assessment (IGA) score for the whole body and for the face only. |  |  | 
| Pruritus (itch) severity assessments, and patient's self-assessment of disease control at the start of study and on day 7, 30 and 90 after treatment initiation. |  |  | 
| Safety assessed by adverse events. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atopic dermatitis, eczema, mild to moderate, children, IGA